ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Repurposing FDA approved drugs targeting IL-6 associated signalling for the management of rheumatoid arthritis: an in silico and experimental approach.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that is mediated by pro-inflammatory cytokines, like interleukin-6 (IL-6). IL-6 plays an important role in synovial inflammation and joint degradation. In this study, a combined in silico, in vitro and in vivo approach was used to identify and preliminarily evaluate valganciclovir hydrochloride as potential modulator of IL-6 receptor mediated inflammatory signalling. Docking studies showed that valganciclovir hydrochloride had favourable binding affinity with IL-6 receptor, and interacted stably with active site. ADMET analysis showed that compound possessed desirable ADMET properties, with good absorption and distribution, and low toxicity. Molecular binding free energy indicated stability of the protein-ligand complex. Moreover, 100 ns molecular dynamics simulation showed stable RMSD, with consistent key interactions, suggesting a dynamically stable protein-ligand complex in the physiological environment. Binding assay further demonstrated concentration dependent inhibition of IL-6:IL-6R interaction. Furthermore, in vivo assessment in collagen induced arthritis rats showed that treatment with valganciclovir hydrochloride resulted in marked reduction in disease severity. The treatment groups demonstrated a decrease in paw swelling, ESR, CRP, RF and IL-6 expression. Treatment also reduced downstream inflammatory mediators such as IL-17, MMP-9, p-STAT3, STAT3 and JAK2, suggesting attenuation of IL-6 associated inflammatory signalling In addition, antioxidant enzyme levels were restored with reduction in lipid peroxidation. The results indicate that valganciclovir hydrochloride has favourable binding interactions, and pharmacokinetics, as well as strong anti-inflammatory and anti-arthritic potential. The combined computational and experimental results support the possible involvement of IL-6/JAK2/STAT3 associated signalling pathways in observed anti-arthritic effects of valganciclovir hydrochloride.
Indexed as
Identifiers
42820990What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.